Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Amarin Plcuk's Business Segments
Amarin Plcuk's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
4
Largest Segment
US
Total Revenue
$ 42
Regions Reported
-
Revenue Share by Reportable Segment - FY
- US0%
- Product19.8%
- Licensing and Royalty Revenue4.7%
- Rebates Chargebacks and Discounts0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| US | $ 68 | - |
| Product | $ 8 | 19.8% |
| Licensing and Royalty Revenue | $ 2 | 4.7% |
1 more segments available
Sign in to unlock the full Amarin Plcuk dataset.
Revenue by Product & Service Category - FY
- Product92%
- Licensing and Royalty7.4%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 39 | 92% |
| Licensing and Royalty | $ 3 | 7.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- US0%
- Product19.8%
- Licensing and Royalty Revenue4.7%
- Rebates Chargebacks and Discounts0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| US | $ 68 | - |
| Product | $ 8 | 19.8% |
| Licensing and Royalty Revenue | $ 2 | 4.7% |
1 more segments available
Sign in to unlock the full Amarin Plcuk dataset.
Description of Amarin Plcuk
Amarin Corporation plc is a biopharmaceutical company that develops and commercializes therapeutic products for the treatment of cardiovascular diseases. The company is based in Dublin, Ireland and its main trading venue is the NASDAQ stock exchange in New York.
Amarin has developed a proprietary technology platform called the VASCEPA® (icosapent ethyl) drug product, which is a prescription medicine that is FDA-approved for the treatment of adult patients with severe hypertriglyceridemia (triglyceride levels above 500 mg/dL). Hypertriglyceridemia is a condition where the levels of triglycerides in the blood are elevated, and this can be a risk factor for the development of cardiovascular diseases like heart attacks and strokes.
VASCEPA® is a highly purified omega-3 fatty acid product that has been shown in clinical trials to reduce triglyceride levels in patients with hypertriglyceridemia. It is also believed that VASCEPA® has other beneficial effects on the cardiovascular system, including reductions in inflammation and improvements in lipid profiles.
Amarin is also conducting research into the use of its omega-3 fatty acid technology for the treatment of other cardiovascular and metabolic diseases. The company has a pipeline of clinical development programs that are focused on a range of indications, including cardiovascular risk reduction in patients with statin therapy, chronic kidney disease, and diabetes mellitus.
Since its inception in 1993, Amarin has raised over $1 billion in funding through a combination of public offerings, private placements, and grants. The company has also entered into partnerships with several pharmaceutical companies, including Kowa Pharmaceuticals America, which is responsible for the commercialization of VASCEPA® in the US.
Despite facing competition from other omega-3 fatty acid products on the market, Amarin has been able to maintain a strong position in the hypertriglyceridemia treatment market due to the unique properties of VASCEPA®. The company's strong financial position and ongoing commitment to research and development make it an attractive investment opportunity for investors who are interested in the biopharmaceutical sector.
Amarin has developed a proprietary technology platform called the VASCEPA® (icosapent ethyl) drug product, which is a prescription medicine that is FDA-approved for the treatment of adult patients with severe hypertriglyceridemia (triglyceride levels above 500 mg/dL). Hypertriglyceridemia is a condition where the levels of triglycerides in the blood are elevated, and this can be a risk factor for the development of cardiovascular diseases like heart attacks and strokes.
VASCEPA® is a highly purified omega-3 fatty acid product that has been shown in clinical trials to reduce triglyceride levels in patients with hypertriglyceridemia. It is also believed that VASCEPA® has other beneficial effects on the cardiovascular system, including reductions in inflammation and improvements in lipid profiles.
Amarin is also conducting research into the use of its omega-3 fatty acid technology for the treatment of other cardiovascular and metabolic diseases. The company has a pipeline of clinical development programs that are focused on a range of indications, including cardiovascular risk reduction in patients with statin therapy, chronic kidney disease, and diabetes mellitus.
Since its inception in 1993, Amarin has raised over $1 billion in funding through a combination of public offerings, private placements, and grants. The company has also entered into partnerships with several pharmaceutical companies, including Kowa Pharmaceuticals America, which is responsible for the commercialization of VASCEPA® in the US.
Despite facing competition from other omega-3 fatty acid products on the market, Amarin has been able to maintain a strong position in the hypertriglyceridemia treatment market due to the unique properties of VASCEPA®. The company's strong financial position and ongoing commitment to research and development make it an attractive investment opportunity for investors who are interested in the biopharmaceutical sector.
Amarin Corporation, a prominent pharmaceutical company, concentrates on developing and commercializing innovative prescription medicines primarily targeting cardiovascular diseases. With a particular focus on managing high triglyceride levels, which are linked to severe health risks such as heart attacks and strokes, Amarin offers various segments, products, and services tailored to improve patient outcomes in this critical area.
Segments:
1. Vascepa:
- Amarin’s flagship product, Vascepa, is a unique formulation of an omega-3 fatty acid derived from fish oil. Unlike other omega-3 supplements, Vascepa is a highly purified product and is the only prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating high triglyceride levels specifically in patients with severe hypertriglyceridemia. This segment underscores Amarin’s commitment to providing effective and scientifically-backed solutions for patients at risk of cardiovascular events.
2. Research and Development:
- Amarin invests significantly in research and development to uncover new treatment possibilities for cardiovascular diseases. The R&D segment draws on advanced lipid science and ongoing clinical trials to innovate and refine therapeutic approaches targeting lipid metabolism, offering potential new products addressing various levels and forms of cardiovascular risk. This continuous commitment to research ensures that Amarin remains at the forefront of scientific advancement in treating cardiovascular conditions.
Products:
1. Vascepa Capsules:
- These soft gelatin capsules contain highly purified eicosapentaenoic acid (EPA), designed specifically for adults with severe hypertriglyceridemia. Vascepa Capsules are formulated to lower elevated triglyceride levels effectively, making them a crucial treatment option for patients who are at a higher risk for cardiovascular diseases.
2. Vascepa Oral Suspension:
- Recognizing the need for alternative delivery methods for certain patient populations, Amarin offers a liquid formulation of Vascepa. This oral suspension is particularly beneficial for patients who may have difficulty swallowing capsules, ensuring wider accessibility to treatment. The oral suspension maintains the same therapeutic properties as the capsules, providing flexibility in dosing without compromising effectiveness.
Services:
1. Medical Information Services:
- Amarin provides comprehensive medical information services that cater to healthcare professionals and patients. This service includes offering detailed data about Vascepa, discussing potential drug interactions, and guiding the correct dosing and usage. Amarin is committed to ensuring that both healthcare providers and patients have access to the most accurate and up-to-date medical information to support safe and effective treatment.
2. Patient Support Services:
- Understanding the challenges patients may face in accessing and adhering to treatment, Amarin has developed robust patient support services. These services include co-pay assistance programs that aid patients in affording their medications, drug delivery options that ensure timely access, and ongoing support to help patients stay on therapy. This comprehensive support framework fosters better patient adherence and overall health management.
3. Education and Awareness Programs:
- Amarin takes an active role in promoting education and awareness surrounding cardiovascular health and the role of omega-3 fatty acids. The company conducts programs targeted at both healthcare professionals and patients to raise awareness of the risks associated with high triglyceride levels and the benefits of using Vascepa as a treatment option. Through these initiatives, Amarin aims to enhance understanding and promote proactive management of cardiovascular health.
Conclusion:
In summary, Amarin Corporation stands out as a leading pharmaceutical entity dedicated to advancing treatments for cardiovascular diseases, heavily focusing on addressing high triglyceride levels through its flagship product, Vascepa. With a robust commitment to research and development, Amarin is continuously exploring innovative solutions while offering a diverse range of products and services that empower patients and healthcare providers alike. Through Vascepa Capsules and Oral Suspension, combined with comprehensive medical support and educational initiatives, Amarin is dedicated to improving patient outcomes and combating the prevalence of cardiovascular diseases.
Segments:
1. Vascepa:
- Amarin’s flagship product, Vascepa, is a unique formulation of an omega-3 fatty acid derived from fish oil. Unlike other omega-3 supplements, Vascepa is a highly purified product and is the only prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating high triglyceride levels specifically in patients with severe hypertriglyceridemia. This segment underscores Amarin’s commitment to providing effective and scientifically-backed solutions for patients at risk of cardiovascular events.
2. Research and Development:
- Amarin invests significantly in research and development to uncover new treatment possibilities for cardiovascular diseases. The R&D segment draws on advanced lipid science and ongoing clinical trials to innovate and refine therapeutic approaches targeting lipid metabolism, offering potential new products addressing various levels and forms of cardiovascular risk. This continuous commitment to research ensures that Amarin remains at the forefront of scientific advancement in treating cardiovascular conditions.
Products:
1. Vascepa Capsules:
- These soft gelatin capsules contain highly purified eicosapentaenoic acid (EPA), designed specifically for adults with severe hypertriglyceridemia. Vascepa Capsules are formulated to lower elevated triglyceride levels effectively, making them a crucial treatment option for patients who are at a higher risk for cardiovascular diseases.
2. Vascepa Oral Suspension:
- Recognizing the need for alternative delivery methods for certain patient populations, Amarin offers a liquid formulation of Vascepa. This oral suspension is particularly beneficial for patients who may have difficulty swallowing capsules, ensuring wider accessibility to treatment. The oral suspension maintains the same therapeutic properties as the capsules, providing flexibility in dosing without compromising effectiveness.
Services:
1. Medical Information Services:
- Amarin provides comprehensive medical information services that cater to healthcare professionals and patients. This service includes offering detailed data about Vascepa, discussing potential drug interactions, and guiding the correct dosing and usage. Amarin is committed to ensuring that both healthcare providers and patients have access to the most accurate and up-to-date medical information to support safe and effective treatment.
2. Patient Support Services:
- Understanding the challenges patients may face in accessing and adhering to treatment, Amarin has developed robust patient support services. These services include co-pay assistance programs that aid patients in affording their medications, drug delivery options that ensure timely access, and ongoing support to help patients stay on therapy. This comprehensive support framework fosters better patient adherence and overall health management.
3. Education and Awareness Programs:
- Amarin takes an active role in promoting education and awareness surrounding cardiovascular health and the role of omega-3 fatty acids. The company conducts programs targeted at both healthcare professionals and patients to raise awareness of the risks associated with high triglyceride levels and the benefits of using Vascepa as a treatment option. Through these initiatives, Amarin aims to enhance understanding and promote proactive management of cardiovascular health.
Conclusion:
In summary, Amarin Corporation stands out as a leading pharmaceutical entity dedicated to advancing treatments for cardiovascular diseases, heavily focusing on addressing high triglyceride levels through its flagship product, Vascepa. With a robust commitment to research and development, Amarin is continuously exploring innovative solutions while offering a diverse range of products and services that empower patients and healthcare providers alike. Through Vascepa Capsules and Oral Suspension, combined with comprehensive medical support and educational initiatives, Amarin is dedicated to improving patient outcomes and combating the prevalence of cardiovascular diseases.